Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro

Cancer Letters

Volumn 305, Issue 1, 2011, Pages 32-39

  Miyazawa, Motoki ^a   Iwahashi, Makoto ^a   Ojima, Toshiyasu ^a   Katsuda, Masahiro ^a   Nakamura, Masaki ^a   Nakamori, Mikihito ^a   Ueda, Kentaro ^a   Naka, Teiji ^a   Hayata, Keiji ^a   Iida, Takeshi ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Cytotoxic T lymphocytes; Dendritic cells; Mesothelin

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; GAMMA INTERFERON; MESOTHELIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG SPECIFICITY; EPITOPE MAPPING; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOBLASTOID CELL; LYMPHOCYTE ACTIVATION; MSLN GENE; NONHUMAN; ONCOGENE; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DNA, COMPLEMENTARY; GENETIC VECTORS; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 79953210704     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.013     Document Type: Article

References (49)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
2. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995. Using the National Cancer Database. J. Am. Coll. Surg. 1999, 189:1-7.
3. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
4. Laheru D., Jaffee E.M. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 2005, 5:459-467.
5. Gjertsen M.K., Buanes T., Rosseland A.R., et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 2001, 92:441-450.
6. Ramanathan R.K., Lee K.M., McKolanis J., et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 2005, 54:254-264.
7. Marshall J.L., Gulley J.L., Arlen P.M., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 2005, 23:720-731.
8. Laheru D., Lutz E., Burke J., et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 2008, 14:1455-1463.
9. Bernhardt S.L., Gjertsen M.K., Trachsel S., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Brit. J. Cancer 2006, 95:1474-1482.
10. Miyazawa M., Ohsawa R., Tsunoda T., et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2009, 101:433-439.
11. Argani P., Iacobuzio-Donahue C., Ryu B., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 2001, 7:3862-3868.
12. Ordonez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 2003, 27:1418-1428.
13. Li M., Bharadwaj U., Zhang R., et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol. Cancer Ther. 2008, 7:286-296.
14. Hassan R., Bera T., Pastan I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 2004, 10:3937-3942.
15. Hassan R., Bullock S., Premkumar A., et al. Phase I study of SS1P. A recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 2007, 13:5144-5149.
16. Hassan R., Schweizer C., KF Lu., et al. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 2010, 68:455-459.
17. Yokokawa J., Palena C., Arlen P., et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin. Cancer Res. 2005, 11:6342-6351.
18. Chang C.L., Wu T.C., Hung C.F. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther. 2007, 14:1189-1198.
19. Hung C.F., Calizo R., Tsai Y.C., et al. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007, 25:127-135.
20. Feng Y., Xiao X., Zhu Z., et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol. Cancer Ther. 2009, (Epub ahead of print).
21. Song W., Kong H.L., Carpenter H., et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 1997, 186:1247-1256.
22. Nakamura M., Iwahashi M., Nakamori M., et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin. Cancer Res. 2002, 8:2742-2749.
23. Ojima T., Iwahashi M., Nakamura M., et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int. J. Cancer 2007, 120:585-593.
24. Ojima T., Iwahashi M., Nakamura M., et al. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Int. J. Oncol. 2008, 32:459-466.
25. Lee A.W., Truong T., Bickham K., et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002, 20(Suppl 4):A8-A22.
26. Ueda K., Iwahashi M., Nakamori M., et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001, 61:6158-6162.
27. Ojima T., Iwahashi M., Nakamura M., et al. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. Int. J. Oncol. 2007, 31:931-939.
28. Thomas A.M., Santarsiero L.M., Lutz E.R., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 2004, 200:297-306.
29. Perez-Diez A., Butterfield L.H., Li L., et al. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 1998, 58:5305-5309.
30. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996, 93:136-140.
31. Frierson H.F., Moskaluk C.A., Powell S.M., et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum. Pathol. 2003, 34:605-609.
32. Hassan R., Laszik Z.G., Lerner M., et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 2005, 124:838-845.
33. Ho M., Bera T.K., Willingham M.C., et al. Mesothelin expression in human lung cancer. Clin. Cancer Res. 2007, 13:1571-1575.
34. Dainty L.A., Risinger J.I., Morrison C., et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol. Oncol. 2007, 105:563-570.
35. Steinbach D., Onda M., Voigt A., et al. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur. J. Haematol. 2007, 79:281-286.
36. Watanabe H., Okada G., Ohtsubo K., et al. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas 2005, 30:349-354.
37. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63:8614-8622.
38. Maitra A., Adsay N.V., Argani P., et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. 2003, 16:902-912.
39. Gubbels J.A., Belisle J., Onda M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 2006, 5:50.
40. Rump A., Morikawa Y., Tanaka M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 2004, 279:9190-9198.
41. Ordonez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol. 2003, 16:192-197.
42. Chang K., Pai L.H., Batra J.K., Pastan I., Willingham M.C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992, 52:181-186.
43. Jaffee E.M., Hruban R.H., Biedrzycki B., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor - secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19:145-156.
44. Johnston F.M., Tan M.C., Tan B.R., et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin. Cancer Res. 2009, 15:6511-6518.
45. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
46. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
47. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 2008, 222:129-144.
48. Nakamura M., Iwahashi M., Nakamori M., et al. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 2005, 68:163-170.
49. Hung C.F., Tsai Y.C., He L., et al. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 2007, 14:921-929.